Last checked at 3 Aug 2022 14:55
3 August 2022
Cambridge Cognition Holdings Plc
("Cambridge Cognition", the "Company" or the "Group")
Directorate Change
Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that further to the announcement of 6 April 2022, Stephen Symonds, Chief Financial Officer, has been appointed to the Board of Cambridge Cognition as an Executive Director with immediate effect.
Stephen was previously the CFO of Envigo, a provider of pre-clinical services to the pharmaceutical industry, where he spent eight years. Prior to that, Stephen spent a decade with KPMG, working on a wide-ranging portfolio of clients.
Steven Powell, Chairman of the Company, commented: "We are delighted that Stephen is joining the Board. He has extensive relevant experience and has fitted in very well with the team since joining the Company in April this year."
Additional Information in respect of the AIM Rules
The following information regarding the appointment of Stephen Daniel Symonds, aged 47, is disclosed under Schedule Two paragraph (g) of the AIM Rules for Companies:
Current Directorships | Previous Directorships (within the last five years) |
Centralabs Clinical Research Limited | |
Covance Consulting Limited | |
Covance CRS Analytics Limited | |
Covance CRS Developments Limited | |
Covance CRS International Limited | |
Covance Pharma Consulting Limited | |
Envigo CRS (Switzerland) Limited | |
Envigo CRS GmbH | |
Envigo CRS Israel Limited | |
Envigo CRS SA | |
Envigo CRS Switzerland Limited | |
Envigo Holdings Limited | |
Envigo Monitoring Limited | |
Envigo RMS (UK) Limited | |
Envigo RMS BV | |
Envigo RMS GmbH | |
Envigo RMS India Private Limited | |
Envigo RMS Israel Limited | |
Envigo RMS Sarl | |
Envigo RMS SL | |
Envigo RMS Srl | |
Envigo Ventures Limited | |
Harlan Eurasia Holdings Limited | |
Harlan Europe Holdings Limited | |
HIH Limited | |
Huntingdon Consulting Engineers Limited | |
Huntingdon Research Centre Limited | |
Labcorp Research Limited | |
Labcorp UK Limited | |
Paragon Global Services Limited | |
Pathfinder Clinical Development Limited | |
Pathfinder Nominees Limited | |
Servicepharm Limited |
As at the date of this announcement, Stephen Symonds holds 22,950 ordinary shares in the Company representing 0.07% of the Company's issued share capital. In addition, Stephen holds an interest in 152,671 options over ordinary shares of the Company.
Save as set out above there are no further disclosures pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies in respect of the appointment of Stephen Symonds.
For further information, please contact:
Cambridge Cognition Holdings Plc | Tel: 01223 810 700 |
Matthew Stork, Chief Executive Officer | press@camcog.com |
Stephen Symonds, Chief Financial Officer | |
Panmure Gordon (UK) Ltd (NOMAD and Joint Broker) |
Tel: 020 78862500 |
Freddy Crossley / Emma Earl / Mark Rodgers | (Corporate Advisory) |
Rupert Dearden | (Corporate Broking) |
Dowgate Capital Limited (Joint Broker) | Tel: 020 3903 7715 |
David Poutney / James Serjeant | |
IFC Advisory Ltd (Financial PR and IR) | Tel: 020 3934 6630 |
Tim Metcalfe / Graham Herring / Zach Cohen | cog@investor-focus.co.uk |
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.
For further information visit www.cambridgecognition.com